INTS INTENSITY THERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1567264 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.6%
TTM EPS YoY90.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-161.8%
ROA-121.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-29.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.43M | $1.83M | $1.20M | $1.50M | $1.55M | $1.54M | $2.19M | $1.97M |
| SG&A expense | $1.19M | $1.25M | $1.33M | $1.64M | $1.18M | $1.16M | $1.21M | $1.24M |
| Operating income | -$3.62M | -$3.08M | -$2.53M | -$3.14M | -$2.73M | -$2.71M | -$3.39M | -$3.20M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Net income | -$3.54M | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | -$3.35M | -$3.18M |
| EPS (basic) | -1.09 | -1.11 | -0.96 | — | -1.55 | -3.36 | -5.51 | — |
| EPS (diluted) | -1.09 | -1.11 | -0.96 | — | -1.55 | -3.36 | -5.51 | — |
| Weighted avg. shares (diluted) | 3.26M | 2.71M | 2.53M | — | 1.72M | 754,725 | 606,928 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.49M | $9.53M | $10.24M | $11.92M | $7.07M | $2.22M | $929,000 | $2.59M |
| Receivables | $41,278 | — | — | — | — | — | — | — |
| Current assets | $9.50M | $11.23M | $10.91M | $12.71M | $8.19M | $3.04M | $1.65M | $3.36M |
| Total assets | $10.29M | $11.52M | $12.29M | $14.10M | $9.59M | $4.44M | $3.06M | $4.78M |
| Current liabilities | $2.58M | $2.25M | $2.24M | $2.15M | $2.28M | $2.16M | $2.63M | $1.75M |
| Total liabilities | $2.63M | $2.31M | $2.31M | $2.23M | $2.36M | $2.26M | $2.73M | $1.86M |
| Shareholders' equity | $7.65M | $9.21M | $9.98M | $11.88M | $7.22M | $2.18M | $334,000 | $2.92M |
| Shares outstanding | 3.30M | 2.95M | 2.54M | 2.52M | 49.07M | 26.17M | 15.26M | 604,915 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.50M | -$2.34M | -$1.83M | -$2.40M | -$2.39M | -$2.46M | -$1.99M | -$2.67M |
| Investing cash flow | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $1.47M | $1.62M | $150,000 | $7.25M | $7.24M | $3.74M | $328,000 | $2.48M |
| Stock-based compensation | $517,000 | $387,000 | $387,000 | $450,000 | $471,000 | $644,000 | $435,000 | $844,000 |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.